Literature DB >> 30992137

Learning from a clinical cohort for HCV vaccine development.

Florian Wrensch1, Zhen-Yong Keck2, Steven K H Foung2, Thomas F Baumert3.   

Abstract

Entities:  

Keywords:  Antibody; B-cell response; Hepatitis C virus; Neutralization

Mesh：

Substances：

Year:  2019        PMID： 30992137      PMCID： PMC7613475          DOI： 10.1016/j.jhep.2019.03.030

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   30.083


× No keyword cloud information.
  20 in total

1.  Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.

Authors:  Zhen-Yong Keck; Anasuya Saha; Jinming Xia; Yong Wang; Patrick Lau; Thomas Krey; Felix A Rey; Steven K H Foung
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

2.  Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.

Authors:  Thomas H R Carlsen; Jannie Pedersen; Jannick C Prentoe; Erick Giang; Zhen-Yong Keck; Lotte S Mikkelsen; Mansun Law; Steven K H Foung; Jens Bukh
Journal:  Hepatology       Date:  2014-10-02       Impact factor: 17.425

Review 3.  A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing.

Authors:  Thomas F Baumert; Catherine Fauvelle; Diana Y Chen; Georg M Lauer
Journal:  J Hepatol       Date:  2014-11-03       Impact factor: 25.083

4.  Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.

Authors:  Sabrina J Merat; Camille Bru; Dorien van de Berg; Richard Molenkamp; Alexander W Tarr; Sylvie Koekkoek; Neeltje A Kootstra; Maria Prins; Jonathan K Ball; Arjen Q Bakker; Menno D de Jong; Hergen Spits; Tim Beaumont; Janke Schinkel
Journal:  J Hepatol       Date:  2019-02-21       Impact factor: 25.083

5.  Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study.

Authors:  Rachel Sacks-Davis; Jason Grebely; Gregory J Dore; William Osburn; Andrea L Cox; Thomas M Rice; Timothy Spelman; Julie Bruneau; Maria Prins; Arthur Y Kim; Barbara H McGovern; Naglaa H Shoukry; Janke Schinkel; Todd M Allen; Meghan Morris; Behzad Hajarizadeh; Lisa Maher; Andrew R Lloyd; Kimberly Page; Margaret Hellard
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

6.  Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection.

Authors:  Dimitri Lavillette; Yoann Morice; Georgios Germanidis; Peggy Donot; Alexandre Soulier; Emanuil Pagkalos; Georgios Sakellariou; Liliane Intrator; Birke Bartosch; Jean-Michel Pawlotsky; François-Loïc Cosset
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.

Authors:  Erick Giang; Marcus Dorner; Jannick C Prentoe; Marlène Dreux; Matthew J Evans; Jens Bukh; Charles M Rice; Alexander Ploss; Dennis R Burton; Mansun Law
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-04       Impact factor: 11.205

8.  Rational HIV immunogen design to target specific germline B cell receptors.

Authors:  Joseph Jardine; Jean-Philippe Julien; Sergey Menis; Takayuki Ota; Oleksandr Kalyuzhniy; Andrew McGuire; Devin Sok; Po-Ssu Huang; Skye MacPherson; Meaghan Jones; Travis Nieusma; John Mathison; David Baker; Andrew B Ward; Dennis R Burton; Leonidas Stamatatos; David Nemazee; Ian A Wilson; William R Schief
Journal:  Science       Date:  2013-03-28       Impact factor: 47.728

9.  Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection.

Authors:  William O Osburn; Brian E Fisher; Kimberly A Dowd; Giselle Urban; Lin Liu; Stuart C Ray; David L Thomas; Andrea L Cox
Journal:  Gastroenterology       Date:  2009-09-24       Impact factor: 22.682

10.  Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.

Authors:  Mansun Law; Toshiaki Maruyama; Jamie Lewis; Erick Giang; Alexander W Tarr; Zania Stamataki; Pablo Gastaminza; Francis V Chisari; Ian M Jones; Robert I Fox; Jonathan K Ball; Jane A McKeating; Norman M Kneteman; Dennis R Burton
Journal:  Nat Med       Date:  2007-12-06       Impact factor: 53.440
View more
  2 in total

Review 1.  Hepatitis C virus: A critical approach to who really needs treatment.

Authors:  Elias Kouroumalis; Argyro Voumvouraki
Journal:  World J Hepatol       Date:  2022-01-27

2.  Serum neutralization activity declines but memory B cells persist after cure of chronic hepatitis C.

Authors:  Akira Nishio; Sharika Hasan; Heiyoung Park; Nana Park; Jordan H Salas; Eduardo Salinas; Lela Kardava; Paul Juneau; Nicole Frumento; Guido Massaccesi; Susan Moir; Justin R Bailey; Arash Grakoui; Marc G Ghany; Barbara Rehermann
Journal:  Nat Commun       Date:  2022-09-16       Impact factor: 17.694
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.